Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.
D000368:Aged; D000789:Angina, Unstable / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D015415:Biomarkers; D002097:C-Reactive Protein / Q000032:analysis; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D004318:Doxycycline / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood; D007378:Interleukins / Q000097:blood; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D061965:Matrix Metalloproteinase Inhibitors; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D010865:Pilot Projects; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012422:Rupture, Spontaneous; D019210:Troponin I / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D007378:Interleukins; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D019210:Troponin I; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D020780:Matrix Metalloproteinase 9; D004318:Doxycycline